Skip to main content
. 2013 Apr;57(4):1756–1762. doi: 10.1128/AAC.01232-12

Fig 3.

Fig 3

Clinical responses in phase 2 and phase 3 hospital-acquired pneumonia (HAP) trials, comparing different doses of tigecycline (TGC) and imipenem/cilastatin (IMI/CIL; 70% confidence intervals). CE, clinically evaluable; c-mITT, clinical modified intention to treat.